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Abstract. Clinical research is increasingly conducted in settings that include private physicians’ offices, clinics,
community hospitals, local institutes, and independent research centers. The migration of such research into this
new, non–academic environment has brought new cadres of researchers into the clinical research enterprise
and also broadened the pool of potential research participants. Regulatory approaches for protecting human
subjects who participate in research have also evolved. Some institutions retain their own Institutional Review
Boards (IRBs), but Independent IRBs, community hospital IRBs and community–based IRBs also fulfill oversight
responsibilities. This article sheds light on this evolving world by discussing the findings gleaned from two
studies: a study of the decision making processes used by members who serve on different kinds of IRBs and a
study of the decision making processes employed by research participants. The article then discusses how the
key findings may inform proposed revisions to the Common Rule.
Key Words. Human subject research, IRBs, clinical trials, protection of human subjects, Common Rule

Introduction: A Changing Landscape
Before the 1980s, most of the revenue for medical
research conducted in the United States came from
federal grants. Federal support of basic research
led to the first vaccines for the flu, polio, and other
childhood diseases. Other medical advances made
with federal support include the discoveries of
neurotransmitters in the brain, identification of
over 20 cancer–related genes, and demonstration
that cholesterol levels are linked with potential

heart attacks (United States Senate, 2000). Cancer
treatment drugs such as Paclitaxel (Taxol, Bristol–Meyers–Squibb, Princeton, NJ) have been
developed and clinically tested in humans with
funding from the National Cancer Institute (Nader
& Love, 1993). Such federally supported research
has been primarily conducted in prestigious academic medical centers such as the Mayo Clinic,
Johns Hopkins, Sloan Kettering, Mt. Sinai, and
MD Anderson, which are located in large, mostly
urban communities.

Narrative Inquiry in Bioethics Volume 3.1 (2013) 51–65 © 2013 by The Johns Hopkins University Press

52 Narrative Inquiry in Bioethics • Volume 3 • Number 1 • Spring 2013

The world of clinical research has changed over
the last 30 years. Federal funding for research has
decreased and industry funding has steadily escalated; by 1991, industry funding outpaced federal
funding, and by 2000, 70% of clinical trials were
funded by industry (Bodenheimer, 2000). Some
industry research is focused on the development
of new or novel drugs, but considerable industry
effort is directed toward commercial interests such
as extending patents, finding new uses for existing drugs, developing “me–too” drugs to secure a
market share, and assessing prescription practices
(Kottow, 2009). The change in the research venue
is also notable; most clinical research has migrated
to nonacademic environments. Although industry
funding for clinical research has steadily increased
(Congressional Budget Office, 2006), the share of
funding for such research conducted in academic
medical centers declined from 80% in 1991 (Klein
& Fleischman, 2002) to 35% in 2005 (Fisher, 2006),
and the decline has continued (Fisher, 2006, 2007;
Shuchman, 2007; Sox, 2001). Currently, most industry research, including disease–specific studies as
well as genetics and pharmacogenomics research,
takes place in settings unaffiliated with academic
medical centers, such as private physicians’ offices,
research institutes, hospitals, and clinics (Chen,
Miller, & Rosenstein, 2003; Klein & Fleischman,
2002). Federally funded research, such as the Clinical Trials Cooperative Group Program sponsored
by the National Cancer Institute, is also moving
to community–based settings (National Cancer
Institute, 2009).
As the world of clinical research has evolved, so
too have the regulatory approaches for protecting
those who become research subjects. Institutional
review boards (IRBs) serve as key oversight bodies
for monitoring research that involves human participants. They are charged with evaluating the risks
and benefits, subject selection methods, informed
consent process, and methods for protecting privacy
and confidentiality. At one time, institutions relied
primarily on the work of their own institutionally
supported IRBs to fulfill these oversight responsibilities. As a result of recent changes in the structure,
setting, and funding of clinical research, although

many institutions still retain their own IRBs, new
models such as independent IRBs (Macklin, 2008),
community hospital IRBs (Hall et al., 2009), and
community–based IRBs now perform oversight
functions (Jansen, 2005). Many clinical studies that
are approved by independent IRBs are conducted in
multiple sites and in multiple states (Christensen &
Orlowski, 2005). Even institutions that retain their
own IRBs may choose to submit certain kinds of
studies to other IRBs rather than performing an
in–house review.
Although a robust literature base explores the
ethical, legal, and regulatory challenges associated with the protection of human subjects, there
is a growing sense that, as Michael Kottow (2009)
cautions, “the agility of biomedical research far
outstrips the pace of research ethics.” He is not
alone in his concerns. In an effort to keep pace with
the changing times, the U.S. Department of Health
and Human Services (HHS) has launched a process
to revise the Common Rule. On July 26, 2011, HHS
issued an advance notice of proposed rulemaking
(ANPRM) to solicit public comments on “how
current regulations for protecting human subjects
who participate in research might be modernized
and revised to be more effective” (U.S. HHS, 2011).
The intent behind the rulemaking involves efforts
to both enhance protections for subjects and reduce
delay and burden for investigators. Section IV of
the ANPRM focuses on efforts to improve informed
consent and determine what a person needs to
know to make an enlightened decision to enroll in
a research study. This section highlights a number
of broad concerns about current requirements for
informed consent forms. For example, question 40
of the ANPRM specifically asks whether informed
consent would be improved if regulations included
additional requirements regarding the consent
process and, if so, what should be required. The
comments submitted to HHS become part of the
public record. Lodged primarily by researchers
and institutional representatives, these comments
provide an indication of evolving perspectives
within the scientific community. All submitted
comments, along with the name of the commenter,
can be viewed online (U.S. HHS, 2011).

What Regulators and Researchers Can Learn from IRB Members and Subjects

Given the changing research environment, it
seems useful to examine the perspectives that both
“the protectors and the protected” bring to the
discussion about informed consent and specifically
the kinds of information most important to include
in consent forms. This commentary first discusses
the findings that emerged from two studies: an
exploration of the decision–making processes used
by members who serve on different kinds of IRBs
(Cook & Hoas, 2011a, b) and an exploration of the
decision–making processes employed by research
participants (Cook & Hoas, 2011c). This discussion
sheds light on IRB members’ deliberations when
reviewing research protocols and the values, needs,
and experiences of the research participants. It
then presents some of the comments submitted to
the ANPRM process in an effort to appreciate the
range of opinions within the research community
and highlight areas where there may be a lack of
agreement about what may be needed to optimize
the protection of human subjects.

Research Methodology
The IRB study and the Research Participant study
were funded by the National Science Foundation.
Both studies were inductive and contextual in
nature (Miles & Huberman, 1994; Strauss & Corbin,
1990), an approach well–suited to the exploration
of these complex phenomena and relationships.
The studies analyze key informant interviews with
IRB members and research participants who live
in rural and urban settings. The sampling strategy
was designed to maximize respondent variation
to facilitate examination of information–rich cases,
detect patterns spanning differences within and
among the various stakeholder cohorts and settings,
and optimize confidentiality. To create a national
sample for the IRB study, the investigators first
identified all IRBs holding a Federal–Wide Assurance Number from the Office of Human Research
Protections. IRBs were categorized according to
type, and a purposive sample was selected so as to
include seven groups or types: IRBs that serve in
universities with and without medical schools, IRBs
from both rural and urban hospitals, community
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IRBs from both rural and urban communities, and
for–profit IRBs that typically serve researchers in
several states. Once selected, the IRB was contacted
via phone or email, and a member was invited to
participate in the study. A minimum of four to six
key informants were selected from each type of IRB
for a total of 40 participants.
To obtain a national sample of research participants, the investigators designed a geographically
diverse sample of facilities that engage in health
research, including hospitals, clinics, mental health
centers, and private practice settings. Healthcare
personnel were contacted, given information about
the study, and asked to verbally share information
about the study with patients or post information
about the study in their facilities. Persons interested
in participating could then contact the investigators
and schedule an interview. The sample of research
participants was composed of 33 females and 17
males. The education level of participants was high
with 87% reporting at least some college education.
After conducting 50 interviews, no new information
was emerging; it was determined that saturation
had been achieved and the interview process was
suspended.
For both studies, the investigators used semistructured instruments that employed core questions
while also allowing for exploration of unanticipated
or emerging issues. The interviews were conducted
by phone and transcribed verbatim. Most interviews lasted about an hour. With the aid of Atlas.ti
software, the data were coded and organized into
themes that could then be compared and contrasted.
This approach allowed the investigators to obtain
“yes” and “no” responses that could be calculated
as well as lengthy explanations that showcased
the processes for making decisions. Throughout
the manuscript, representative quotes are used to
provide a general view of the interviewees’ perspectives. The interview data obtained from these studies provide a rich repository of insights from those
who serve in a regulatory function (IRB members)
and those for whom the regulations are designed
to protect (human research subjects). Although
the authors’ prior publications detail each study’s
research methodology and overall findings, this
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article combines, compares, and contrasts key findings and themes of those two studies. By juxtaposing the words and phrases of those who protect (IRB
members) and of those who are protected (research
participants), the article attempts to expand awareness and appreciation of where we are and what it
might take to foster a system that truly optimizes
protection of human subjects through the consideration of all voices and concerns.

Protecting Subjects’ Rights and Welfare
The IRB Perspective
The findings from the IRB study suggest that IRB
members view their responsibility to protect the
rights and welfare of human subjects in a very
serious light. Indeed, members of all types of
IRBs—academic, hospital, community/tribal, and
independent—often described their IRB service as
a “calling” and as a “mission.” Members from all
types of IRBs frequently referenced the ethical violations of past studies like Tuskegee and the need
to ensure such ethical deviations do not re–occur.
Most IRB members described their IRB service as
very time intensive, often unappreciated, and at
times burdensome, but also very important; they
reported that the numbers of studies under review
were increasing, study protocols were often complicated, and the decisions they made influenced
research conducted in diverse rural and urban
populations. Members reported that many hours
were expended in the process of carefully reading
the materials submitted to the IRB and attending
the scheduled meetings. Although the work was
described as challenging and difficult, all of the
members spoke of its importance and reported that
their IRBs “do a good job” (Cook & Hoas, 2011a, b).
However, the findings from the IRB study also
suggested that—despite members’ commitment,
good intentions, and hard work—efforts to protect
human subjects may fall short of the mark. Most
IRBs used, as a central strategy for optimizing
the protection of human subjects, careful scrutiny
and management of the informed consent form.
The data showed that this strategy was pursued

regardless of the type of IRB. A quote representative
of this approach was offered by an IRB member
who explained: “The focus is on the form. [There
is] little discussion of the context or the process”
(academic IRB). Most IRB members viewed the
form as an essential tool for ensuring a voluntary
and enlightened participant. Explained one IRB
member: “Our process is, first it’s the member
being able to understand, then from the staff point
of view, and then we go over it point by point. You
can have a good reading level, but not representation of what is going to happen” (independent
IRB). Members from other types of IRBs detailed
similar approaches to ensure that the form met
all technical and regulatory requirements. They
offered statements such as: “[IRBs] nitpick every
single word throughout the 35 pages” (medical
school IRB); and “I don’t think we have had hardly
a form that hasn’t been altered to go to a lower level
of readability” (community IRB); and “We strive
for understandability and we look for medical
jargon . . . we have members who are sticklers”
(community IRB).
The need to create a consent document that
clearly conveys essential information was evidenced when members talked about issues such as
assessing risk and benefit. Members offered representative quotes: “So it is the role of the IRB to see
risks and benefits and catch risks. With the help of
committee members that are knowledgeable about
stuff, they catch potential risk and we make changes
to the consent form” (medical school IRB). This
approach seems to reflect an understanding that
the IRB’s job is not to design the research study, but
to recognize risk and make certain it is accurately
conveyed. The following quote sheds light on this
perspective: “It is not the job of the IRB to change
the study. The IRB’s job is to make sure participants
have the best chance of understanding the risks”
(hospital IRB). As another member explained,
“I am not sure how you quantify extent but it is
not unusual for us to clarify, tighten, amplify the
consent form. I am not sure that we see something
that wasn’t in the materials as much as clarify and
bring it out and clean it up and better convey, make
it more understandable” (academic IRB).

What Regulators and Researchers Can Learn from IRB Members and Subjects

IRB members acknowledged the challenge of
developing a consent form that contains all mandated information while still meeting a reading
competency level that seemed to be envisioned as
somewhere between 4th and 9th grades. Tensions
arise with investigators and sponsors who perceive
such scrutiny—and often requirements for word–
by–word changes—as intrusive and a hindrance to
study approval. IRB members acknowledged that
the approved forms were probably too long and
might not be read by research participants. Members asserted, however, that such careful scrutiny
was essential in terms of documenting their regulatory obligations to protect human subjects. The form
was seen as a way to underscore the considerable
efforts undertaken to ensure that decisions of participants were both voluntary and informed.
In addition to careful management of the consent form, members also explained that they carefully evaluated any compensation provided to the
research participant to minimize risks of compensation becoming coercive or unduly influencing a
decision to participate. Indeed, all of the members
felt they had sufficient guidance and authority to
deal with the topic of participant compensation. As
one member explained, “When I see participants
are going to be paid, that is always a flag to talk
about coercion and incentives, especially if it is a
vulnerable population” (community IRB). Another
reported: “Sometimes we hear they want to give a
big bonus and we won’t let them do that” (academic
IRB). IRB members explained that they were so
vigilant about participant compensation because
they wanted to ensure that potential participants
truly understood and appreciated the risks associated with participating in research and would not
be swayed by the prospect of compensation.

The Participant Perspective
Most of the participants (42 of 50) interviewed for
this study reported that they read the informed
consent document before enrolling, and most
reported that they had been fully informed (Cook
& Hoas, 2011a, b). Few participants reported negative experiences with the informed consent process;
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most seemed to view the process as routine or as
what one could reasonably expect from a medical
encounter in a professional setting. As one participant stated, “It had a good setting, good information. She slipped out and let me read it and came
back and asked if I had questions” (participant 6).
A series of follow–up questions, however, call
into question the extent to which participants truly
understood and appreciated the purpose of the
consent form, the information it contained, or what
it meant to participate in a research study. The data
suggest that participants’ beliefs and expectations
about healthcare may make it difficult for them
to absorb key information when trying to make
informed decisions about participating in research.
Rather than relying on information provided via the
consent process or the consent form, participants
seemed to make their decisions based on the belief
that participation would serve their best interests.
Other factors that influenced decision making
include beliefs about the trust, skill, and intent of
those who conduct research, the legitimacy of the
setting, and the socially meritorious purpose of
the research. When patients were asked “Why did
you enroll in the study?”, they uniformly reported
that they trusted their doctors and believed that
respected, trusted, and skilled clinicians would
not suggest enrollment in a clinical trial unless it
provided the best option for their care. When asked,
“Who invited you to participate?”, participants
typically referenced the involvement of personal
physicians. Said one participant, “My oncologist. . . . He said ‘Hang on a second.’ He said you
are perfect candidate for [this] study” (participant
43). Other representative comments include: “My
physician suggested it. He is the one that does it”
(participant 46); and “[The] doctor who recruited
me. I trust him completely and I love the man”
(participant 14). Such trust and confidence in the
persons conducting the research seemed to limit the
extent to which participants could seriously discern
the difference between research and treatment or
evaluate statements about the risks and benefits of
research participation.
In addition to mentioning the confidence
entrusted in one’s clinician, participants consistently
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explained that a professionally recognized site—like
a hospital, clinic, or physician’s office—reinforced
their assessment of legitimacy and potential benefit.
As one participant offered when asked to describe
what information was most helpful in terms of making a decision about research participation, “Well,
I think it was because it was credible. It wasn’t just
a piece of paper. It was in the hospital’s surgical
setting. It was not just something in the mall. And
it seemed like there was a benefit and [he] would
get more attention. And it was in the hospital” (participant 10). Others explained: “I guess having gone
in there and if it had been shady—I would have
thought twice. But it was a nice, clean, presentable
place. The professional manner and they were thorough and they had the patient rights information. It
looked like a doctor’s office. They had all the things
that I expect from a doctor’s office” (participant 3);
and “We went out to their office and it was professional. It didn’t look like a store front. They had
coffee and candy bars and they sit down and talk
to you—from the receptionist, nurse, PA or NP, it
was all nice. I met with three people during the first
visit” (participant 18).
Most participants also expressed support for
and confidence in the important work of science,
generally believing that medical studies were
designed and conducted to benefit both the patient
and humankind. Thus, in addition to providing
personal benefit to one who enrolls, most participants also alluded to the benefits gained for society,
and described hopes that research would find new
cures, create miracle drugs, and reduce suffering
in generations to come. They spoke of advances
that had been made such as the polio vaccine and
the treatments for AIDS and cancer. Representative
quotes included: “I saw it as an obligation and it
may have benefits to someone else” (participant 6);
and “The other reason was very strong in my mind
was maybe I would be doing something positive
for science and for people. I would contribute. That
was big in my mind” (participant 14); and “Just to
be helpful, to help these peoples’ plight and further
the research” (participant 37).
Given this multilayered trust that the participants found in the person, the place, and the

purpose of research, most seemed disinclined to
seriously examine key information in the consent
form including the statements of benefits and risks.
This was evident when persons responded to a
series of questions about risks and benefits including: “What did you see as the benefits of participating, what did you see as the risks of participating
and did you see the benefits as outweighing the
risks?” When describing their assessment of the
risks and benefits of participation, most explained
that the benefits outweighed the risks. The data
suggest that those who had enrolled in a clinical
research study typically overestimated the benefits
of participation, noting that it afforded “optimal
personal care” and access to what would become
the “new gold standard.” Participants offered
representative statements like: “Well more for less.
Better care and a better cure. My treatment would
be more complete and there would be less chance of
reoccurrence” (participant 47). Another participant
reported: “By the time I met with the oncologist and
told him I would join, I felt that the whole consent
thing had been much ado about nothing. I would
either get the gold standard or something they
thought was even better. It sounded like a way I
could give back with no real risk at all” (participant 49). This perception of personal benefit was
evidenced by another participant who explained:
“Well, then I started talking myself into it and he
[my doctor] said the D–drug would be the new Lipitor, the miracle drug. That sounds so hopeful. . . .
So I thought well if it works, I would be right in
line and first to get the full treatment” (participant
14). The provision of more time and more tests was
often cited as a validation that, upon enrolling in a
study, one would receive better care.
The risk statements outlined on the consent
forms were generally discounted even when such
statements outlined the potential for serious complications. Participants often explained: “I did not
see any risks.” Many of those who discounted the
risk statements on the consent forms believed that
a study would not be offered by a trusted source,
like one’s personal physician, unless the risks were
minimal. This perspective was shown by statements
like: “Because I don’t presume there are any risks.

What Regulators and Researchers Can Learn from IRB Members and Subjects

They didn’t really talk about them” (participant 38);
and “At the time, I didn’t see it as a risk because I
didn’t even think to ask. . . . And I didn’t think about
it then. I don’t remember that I was alerted to any
problems. I probably wasn’t because I maybe would
have hesitated if I had been alerted” (participant
16). Some participants expressed the belief that the
government would not allow studies—and doctors
would not recommend them—if there were serious
risks. As one participate explained: “But I think
there is an assumption that you make in a way—
that if someone asks you to do this, like if a medical
persons asks you—you think they already know the
risks are minimal and they would not put you at
a great deal of risk. They have your well–being at
heart. That is how most people would think. But it
may not be true. They are doctors. There is the trust
thing” (participant 21).
Even when participants reported that the consent
form identified potential risks, they were not sure
how to assess the importance or relevance of that
information to their personal care. A representative comment is shown by the participant who
explained: “I didn’t see many risks. The only thing
that made it sound like any risk was the blood
thinner and maybe you would be less inclined to
stop bleeding—or maybe you could lose a lot of
blood?” (participant 2). Another explained: “You
had to sign a form that said you might have a heart
attack. I thought it was a formality—like what you
sign before surgery, the form saying you might
die. It was just like the legal language thing on the
consent forms . . . that thing you have on consent
forms like being injured. Yeah. I didn’t take it seriously” (participant 4). One person noted that the
consent form did, in fact, indicate the potential
risk of congestive heart failure, but was reassured
when “the doctor said congestive heart failure was
treatable” (participant 47).
Although consent forms are usually required to
include institutional boilerplate information about
protocols for privacy and confidentiality, most participants seem to lack a framework for appreciating
why those safeguards are required and essential.
Thus, this information was also generally disregarded. Participants expressed few concerns about
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privacy, confidentiality, anonymity, and evolving
issues like banking of blood and tissue samples
and the potential uses of genetic information. Most
did not seem to make distinctions between privacy,
confidentiality, and anonymity. Nearly all of the
participants (42 of 50) believed that the standards
for protection of participants were in place, that
medical information was secure, and that their
interests and well–being were protected. Explaining
their understanding of privacy and confidentiality,
participants offered statements like: “It was private.
I was the only one. I was the only one in the room”
(participant 7) and “Yes. They seem to be careful of
how they are handling phone calls and the personal
upfront interview” (participant 17). When participating in studies that gathered genetic information,
participants were reassured about anonymity when
told they would be de–identified by a numbering
system and offered explanations like: “I would be
assigned a number—that seemed OK” (participant
6). For many patients, concerns about confidentiality and privacy simply did not seem important. This
was shown by people who said: “Didn’t even consider that” (participant 1) and “Yes [adequate protection]. But then I am not paranoid” (participant
5) and “I did think it was OK. They are planning to
do video and audio—I had fleeting thoughts about
medical records and this mental health problem
being on a permanent record for my daughter. But I
think everybody has a mental health issue—so I felt
fine” (participant 15). Reflecting on implications of
participating in a study, a participant explained: “I
have no knowledge of what happened to the data
over time. And see, foolishly, I didn’t think about it”
(participant 7). Others explained: “How can people
possibly understand that?” (participant 6); and “I
think I gave them permission to use information
about me” (participant 33).

The Role of Researcher Compensation
and Other Commercial Considerations
The IRB Perspective
To use a colloquialism, IRB members seem adept
at “looking where the light shines.” Members
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noted that the regulatory guidance for issues like
the content of the informed consent document and
protocols for reviewing participant compensation
are well developed, and IRBs feel competent to
make decisions in such areas. IRB members found
it more difficult, however, to resolve an array of
other issues that influence their approach to review
and, ultimately, the extent to which IRB efforts
truly optimize the protection of human subjects.
A key issue involves the core mission of the IRB,
that is, whose interests should be served? When
trying to explain how they approach their decisions, members routinely noted that they faced
convergent—and at times even competing—goals.
Although the responsibility of protecting human
subjects was uniformly acknowledged as a historic
and key responsibility, IRB members consistently
reported that they are also expected to support the
interests of researchers/institutions and help to
advance discoveries that benefit society. Indeed,
with the exception of one respondent who reported
that protection of human subjects was the sole
goal of the IRB, the other IRB members were very
specific about the expectation and obligation to
manage these additional goals. A representative
comment about the need to support the interests
of peer researchers was explained by a respondent
who noted: “It is the dynamic. Like it is hard for
doctors to turn one another down” (hospital IRB).
Members described the important role that research
fulfilled within their institutions and the complications that could ensue if research was not approved.
This was noted by a person who explained, “It can
be hard to protest too much because the company is
paying you. You are supposed to be thinking about
the safety of the person but it is hard to divorce
the idea of who is paying you” (independent IRB).
Discerning the benefits that accrue to society was
explained by one participant as a “grey zone, not
in the patient’s best interests” but “maybe good in
the long run?” (hospital IRB).
The formula for balancing what can be experienced as three competing goals (protecting subjects,
protecting the interests of researchers/institutions,
and helping to advance discoveries) was not well–
defined. Members noted that conflicts among these

goals can be hard to resolve and that approval of a
study is generally based on a majority vote that may
not reflect the concerns of dissenting individuals.
The tension encountered when trying to balance
convergent goals was reflected by comments such
as: “I wish we could really protect. I think it [IRB]
does primarily, except I am unhappy that the subjects are not protected more” (hospital IRB). Another
respondent explained: “There’s this tension. The
doctors and the scientists will argue that the
research is important. The community people might
not like it and might feel that it is not really fair to
the participants. So there is that tension” (academic
IRB). The challenges that accompany the management of “convergent goals” became apparent when
IRB members described how they approached
three increasingly difficult issues: Evaluation of
the purpose of a study, disclosure and evaluation
of researcher/institutional compensation, and
obtaining awareness of participant needs, values,
and expectations. These issues are challenging in
part because they are not fully addressed by existing federal regulations or IRB member training. For
example, some of the studies under review, mainly
industry–funded studies, are designed to answer
both scientific and commercial questions, such as
development of a “me–too” drug or a change in
formulary to extend a patent. The IRB members
reported that a review generally focuses on the
scientific approach, including the study design,
research protocols, and related issues such as safety,
risk, and effectiveness. Members may not know
about the commercial purposes of a given study and
indeed most noted a lack of regulations about their
role when assessing the merit of studies that are
designed primarily for commercial purposes. Members reported that it was not clear whether the IRB
should require submission of clear and transparent
information about commercial purposes, if or how
such purposes should influence the assessment of
a study’s scientific merits, whether research participants should be informed of commercial purposes,
or how commercial purposes should be evaluated
when considering the study’s potential benefits to
society. These kinds of issues brought to the fore
the challenges posed by what was perceived, by
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the vast majority of IRB members, as the need to
manage convergent goals. Some suggested that an
IRB’s exploration of commercial purposes could
engender charges of “mission creep,” an issue of
concern within their institutions or companies.
Indicative of the tensions that can emerge when
facing this less regulated area of review, members
offered representative comments, such as, “Frankly,
all of these bazillions of trials are a little tweaked
because the patent is running out. All they want is
to maintain the patent. So they tweak the drug a
little bit, change the formularies or combinations
a little, and then that will keep the patent in place.
Should we tell the patients that? But the docs, the
researchers say no. That’s not our business” (hospital IRB). Another member noted, “We have had
questions when people are a little uncomfortable
about the science—like is this a good study? But
there is some other committee that is supposed to
look at the science—that is not our turf. So if it is
not really beneficial—like some kind of a patent
study—we cannot really say much about that”
(hospital IRB). The potential impact of disclosing
and discussing a commercial purpose was summarized by a member who noted: “It is like there is
this fear [among researchers] that if you allow that
kind of disclosure, the whole shebang will fall apart.
People won’t join studies if you give them the whole
truth. The trouble is how informed do people have
to be? If the study was being conducted to extend a
patent—I would not be willing to participate. And
I would want to know that. Definitely. So there is
intentional dishonesty in omitting information that
could sway decisionmaking” (hospital IRB).
Although all IRB members reported that information about the scientific purpose of a study was
disclosed to the IRB, most IRB members reported
that information about the commercial purpose of
a study was not “on the table” (a descriptive often
used by IRB members) during the review process.
Indeed, members reported that they would not
necessarily know if the study involved a commercial purpose such as “tweaking the formulary” of
an existing drug so as to extend a patent, developing a derivative drug to obtain a market share, or
assessing prescription practices. Others noted that
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such issues would be recognized but simply not
discussed. Some IRB members reported a nagging
sense that certain kinds of studies were not necessarily meritorious or truly beneficial to society.
Most noted, however, that any consideration of
commercial purposes would remain “off the table”
until regulatory guidance stipulates otherwise.
There seemed to be a sense, among most IRB
members, that existing regulations create a floor
and a ceiling, leaving limited room for movement.
This status seemed to leave some members with
an uncomfortable and unresolved moral burden.
As one noted, “You get everything approved if you
wait long enough. Especially phase IV marketing:
It’s a lousy drug that sells tremendously well and
has nothing to do with science and it is declared as
research and . . . the physician likes the new drug
and starts prescribing it. This marketing is a very
large part of the studies for our IRB. You become a
cooperator” (independent IRB).
Most IRB members also reported a lack of
guidance about researcher and institutional compensation, noting that it was unclear what should
be disclosed, to whom, when, or how. Whereas
all the IRBs vigorously examine and debate the
compensation provided to research participants,
most of the IRBs represented in this study did not
request or receive detailed information about the
study budget and so knew little about the amounts
or types of researcher and institutional compensation. Members offered comments such as: “That
[compensation for researcher] is not discussed, not
discussed at all. It is definitely something that in
our environment people don’t want to talk about.
It is the unknown” (hospital IRB). Another member
explained: “Totally taboo. Someday this is coming
. . . right now you as the investigator gets this much
money for entering and your university gets this
much and the university likes money” (independent IRB). A member who seemed troubled by the
lack of regulations when dealing with researcher
compensation explained: “This era of transparency
is uncomfortable for an organization that doesn’t
want that stuff [researcher compensation] known
and for the physicians who have had the luxury
of a relationship and contact with industry and
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not having to be open with patients about that”
(hospital IRB).
The data showed that these two issues—disclosing the commercial purposes of research and
disclosing researcher/institutional compensation—
were difficult topics for all IRBs, regardless of type.
The responses to these issues help to exemplify
how the explicit (protecting human subjects) and
implicit (protecting interests of researchers) goals
that shape the IRBs’ mission can become less convergent and more competitive. Members noted
that institutional expectations, practices, and pressures can complicate efforts to both support the
researcher/institution and at the same time protect
the subject. Members of independent or central
IRBs explained that an in–depth exploration of
researcher compensation would be “bad for business” and “we can’t do it unless everyone has to.”
As one member explained: “I can’t remember what
it was, where we commented to each other that the
way the regulation was written left the door open
and didn’t leave room for us to make a comment,
address the issue. The authority or parameters that
we operate under didn’t give us room to question.
I remember we said the regulations say blah, blah,
blah, so we can only do so and so” (independent
IRB). Members of hospital IRBs spoke of their professional relationships with peer researchers and
the unease associated with asking what seemed
like personal questions. A representative comment
was: “There are a lot of conflicts of interest for
someone with an experimental procedure for the
device that they want to put in a patient. And it is
their patient. And they get paid for it. But the IRB
doesn’t do as critical a look at that situation. It is
the fox in charge of the hen house. You make a lot
of money doing practice–based research. A lot.”
Another member noted: “It is a tough spot to be in
as a nurse. You have to gauge when to speak up.
There are repercussions for speaking up—this is a
very politically correct organization and the repercussions get back to you. Not politically OK to ask
questions about things like disclosure of incentives
and you know it” (hospital IRB). Similarly, members
of academic IRBs noted that exploring issues associated with researcher/institutional compensation

could jeopardize professional relationships and
impact issues like tenure or annual personnel evaluations. As one member explained, “The IRB Chair
should be tenured and full professor and someone
who would be hard to touch. A junior professor
couldn’t do that. You can’t have someone without
power” (academic IRB). Another noted that, “If it
is important to the U, you find a way to approve
it” (academic IRB).
Members were asked if they thought research
participants would want to be informed about
the commercial purposes of research and about
researcher compensation. This question seemed to
create a conundrum. Most members reported that
they had little knowledge of the values, expectations, beliefs, competencies, and needs of those
whom they are charged to protect—the research
participants. Members noted the importance of
including community members on the IRB to
facilitate awareness of participant perspectives,
but also acknowledged that it is hard to truly
assess the extent to which such involvement truly
represents the needs of those who may ultimately
participate in research. Some members suspected
that participants may well want to be informed of
commercial purposes before agreeing to enroll in
a study. Indeed, some members reported that they
themselves would certainly want to be informed
of commercial purposes and researcher compensation before participating in a study. However, such
information was not typically viewed as within the
purview of most IRBs and so processes for disclosing such information to participants were not in
place. As one member noted when offering a summary comment about what should be disclosed and
how and why and when, “We don’t have a way to
asses if we protect human subjects. Everything goes
to that point; not even the FDA audit truly looks at
the protection. They look at our records. They ask,
did you document A, B, and C? Not even relevancy
is assessed by FDA” (independent IRB).

The Participant Perspective
To explore how participants view researcher compensation and commercial purposes when enrolling
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in a study, participants were asked a series of
questions that included: “Would you want to be
informed about researcher compensation?” “Would
it matter to you who is paying for or sponsoring
the study?” “Would you want to be told if a study
was being conducted for a commercial purpose like
extending a patent?” “Would that kind of information influence your willingness to be involved?”
“Was there anything that came as a surprise or
was unexpected when participating in the study?”
This series of questions came after participants
had a chance to provide a narrative description of
their research experience and respond to questions
about recruitment, the consent process, their assessment of risk and benefit, and related issues such
as the use of resources and their decision–making
processes. The questions about purpose and compensation seemed to offer participants a different
lens with which to assess their participation. Most
seemed quite surprised when asked if they would
want to receive information about the compensation provided to researchers or institutions that
conduct research. Most had never thought about
such compensation, or were completely unaware
that such compensation was or could be provided.
They offered statements like: “Wow. We didn’t
know that—they get paid for helping to run these
studies? Really?” (participant 47); and “That never
entered my mind that it is a possibility. . . . It’s a
new thought to think about compensation. I guess
I think the doctor wouldn’t get paid” (participant
14); and “But it would not have occurred to me
before I learned a little more about research studies
in general. And how they are funded. As a patient,
it would arouse skepticism. Why are you inviting
me? What is your larger purpose?” (participant 19).
Some participants seemed to believe that if the
researcher received compensation, the amounts
would be minimal. One participant explained: “I
don’t think I would ask about it. It would feel sort
of—not my business. But I would want to know if
the researcher was getting compensation and then I
would be mad if I didn’t. And when there is something like that statement in the consent form—‘the
researcher is getting compensated’—I would think
it was like $10—not anything big. It wouldn’t occur
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to me. The way it is written, it is like they want you
to gloss over it. Not notice it. It is a scary deal. I think
about my parents and they are old and don’t know
about research and could be taken advantage of.
And if there’s a lot of money, how do they decide
what study to suggest?”(participant 4). Another
one said: “Oh. Oh my. Well if they get compensation, they are ethically obligated to tell about it.
Absolutely. If you think you are signing up for this
study and the doc is doing it out of his charitable
response to the world that is one thing. But, if he is
being paid to run this study that is entirely another”
(participant 6).
Most participants (42/50) reported that they
wanted to know about researcher compensation
and that such information could play a role in their
decisions to participate. The implications of providing such disclosure were not clear. Although some
said that such compensation would not necessarily
deter their participation, they also asserted that
they should be told in a very clear and transparent
manner so that they could make informed choices.
Explained one: “People think their physicians are
saviors. You saved me from cancer. That’s how they
want you to see it. I would want to know if they got
compensation for running studies. I would want
more than the blanket statement” (participant 26).
Reflected another: “Docs probably should disclose
[what they get], though they don’t. They wouldn’t
want to disclose because they don’t want patients to
know—it would change their thoughts on it. Some
would think the doc wants me on this study because
he is making money” (participant 30). Still another
explained: “I would feel deceived if someone was
getting an enrollment or other incentive and not tell
me. It would make a difference who was funding
the study. More information should be provided—a
statement like the doctor receives compensation for
research—it is misleading because you think it is on
par with what is happening to you” (participant 8).
Participants also seemed quite surprised when
asked if they wanted to be informed about the
commercial purposes of a study such as extending patents, developing “me–too” drugs to secure
market shares, or assessing prescription practices.
Most seemed to believe that clinical research was
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being conducted to further science and so benefit
humankind. As one person explained: “I assume
it is on the up and up and not so that [the pharmaceutical company] can make a million dollars
marketing the drug. Well, it seems to me that if I
am in the guinea pig group, I want to make sure
it is on the up and up and I am not sacrificing my
body for someone’s bottom line” (participant 13).
Another noted: “I wouldn’t think to ask that. I’d
never think to ask that. But I would like to know”
(participant 20).
Indeed, 45 of the 50 participants asserted that
they wanted to be informed about commercial
purposes, and most stated that disclosure of such
information could influence their decisions about
participation in future research. The statements
offered were emphatic and descriptive: “The purpose of the study . . . yes, I would want to know.
And if it was to extend the patent or something
like that—hmmm that’s dirty. They should tell
about something like that. Not to tell, that does
feel deceptive. I wouldn’t want to be in that kind
of research” (participant 4); and “The full purpose
should be disclosed. Otherwise I feel that is dishonest, just playing with words, semantics. The IRB
should never approve that kind of consent. And I
would lose respect for an IRB that did” (participant
5); and “Extend a patent—hmmm. Yes, I would
definitely want to know that. Then they wouldn’t
be able to do the generic drug. I would want to
know absolutely. Absolutely” (participant 14);
and “People should absolutely be told if they are
trying to extend a patent. That is not to anyone’s
benefit. There are some good things that pharms
come up with—but the bad side is that capitalistic
attitude. Absolutely I want to know. Should you
know, absolutely. We were not told anything about
that” (participant 16); and “Of course. The patient
should be told about the purpose and so they can
decide” (participant 35).
As participants pondered the questions about
disclosure of researcher compensation and commercial purposes, they seemed to reevaluate some
of their previously held beliefs about the varied
purposes for conducting research and why clinicians may choose to participate. The notion that

a clinician might receive payment when conducting research seemed to introduce the notion that
there could also be conflicts of interest—that clinicians might have some loyalties not just to the
individual patient but to the industry or that the
trial might not actually provide optimal personal
clinical care. Likewise, the specter of commercial
purposes seemed to introduce the notion that clinical research, even when conducted in seemingly
legitimate and respected settings, might have goals
other than the betterment of humankind.
It is not clear how the disclosure of such information during the consent process might influence
participants’ decisions to enroll in research studies.
For some, such information would not be a deterrent for participation. One person, commenting
on how disclosure of commercial purposes could
influence future actions noted: “Right off hand, I
would say it wouldn’t but I may have to reconsider
that. I’d have to think about it. I can’t come up right
of the top of my head with what I’d do. But I am
not sure if it would be a decision–breaker. I would
be OK with the general concept” (participant 20).
Another person explained: “What it would do is
tell me that this is a drug that has been around
and so maybe my risk would be less. So if I was
signing up, I might think I might only be taking a
minimal risk. So that would be reassuring. But then
the patent issue—well, it would bother me because
I would understand the patent game—but most
people might not know. You get money for doing
something that is low risk and you can do another
one. The overall deal is that it is bad for society and
good for the person. In the jaded world we know
that this is done to make pharms more money”
(participant 25). For other participants, however, the
specter of commercial purposes would undermine
the legitimacy of the study and could become a
“deal breaker” in terms of their participation.
The data clearly show that most participants
want transparent information about both issues:
The potential commercial purposes of research
and researcher compensation. The vast majority
of participants also felt that it is deceptive not to
fully disclose and that forthright information about
these issues could certainly influence subsequent
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decisions about research participation. Two comments are illustrative: “Yes. I would ask more
questions. If I didn’t know that it was available and
not disclosed, I would trot along, never suspecting anything. If I knew enough to ask if this was a
matter of extending a patent and didn’t receive a
satisfactory response, I would not go into a study.
But I did not know, at the time, to ask the question”
(participant 19); and “Yes. Absolutely. To me that
is such a direct conflict of interest. It seems a no
brainer that you would have to tell people that. I
think most people don’t understand the structure
of how drug testing works and when they are asked
to join a study, they wouldn’t think to ask questions
about stuff like that” (participant 28).

Moving the Conversation Forward
The findings from the two studies have identified
issues that can compromise the protection of human
subjects and lend support to the HHS effort to
revise the Common Rule. Questions 35 through 40
of the ANPRM seem particularly relevant as they
specifically focus on improving informed consent
forms, an issue that was an ongoing concern for
the IRB members who participated in the authors’
study. Question 40 asked whether informed consent
would be improved if investigators were required
to disclose in consent forms certain information
about the financial relationships they have with
study sponsors. Our results suggest that research
subjects are interested in knowing this information.
However, the public comments on this question add
another level of complexity to the debate, demonstrating the wide range of opinion on what should,
or should not, be disclosed to patients, and the role
of IRBs and other committees in reviewing this
information (U.S. HHS, 2011). The views expressed
suggest that there is currently no consensus on
these issues. Some commenters strongly assert that
the investigators should be required to disclose in
consent forms information about financial relationships they have with study sponsors. One commenter with this perspective wrote: “Researchers
and sponsoring Institutions should fully declare all
financial and other relationships related to a study
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and its sponsors to gain and maintain public trust”
(Sage Bionetworks, 2011).
In contrast, several comments suggested that
research subjects may lack the sophistication to
comprehend and assess the significance of potential
financial conflicts. One commenter wrote: “The
sponsor does not believe that investigators should
have to disclose financial relationships with sponsors since subjects are not capable of correctly
interpreting this information. This information is
already captured in the financial disclosure form
and submitted to the FDA at the time of submitting a marketing application” (Boehringer Ingelheim Pharmaceuticals, 2011). Another stated: “No
additions to the consent form are recommended.
Requiring information about financial relationships
is likely to confuse rather than inform subjects about
sponsor and investigator relationships” (Fairview
Health Services, 2011).
A number of commenters questioned the need
for including this requirement, noting that their
institution currently requires such disclosure in consent forms, whereas others suggest that including
this information in the consent form is not necessary
because the vetting of financial conflict of interest is
handled by IRBs or conflict of interest committees.
As one commenter noted, “We believe institutions
should have discretion, but the regulations should
not mandate and determine when participants must
be notified of financial interests of the investigators. This would be just another administrative
burden added to IRB Offices without the hope
for or reality of increasing participant protection.
Institutions already require their investigators to
disclose their financial relationships through their
Conflict of Interest committees/process” (Arizona
State University, 2011).
Some commenters focused on the complexity of
the issue or suggested that no new requirements
should be established until research is done to
determine the need or importance of such disclosures. One commenter with this perspective stated:
“Any proposed additional elements to be included
as part of the informed consent process, such as
when financial interests of investigators should
be disclosed to research subjects, should only be
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considered after further study of what form of interaction is most comprehensible to research subjects”
(University of Pittsburgh, 2011).
These comments, when combined with the
authors’ findings, attest to the challenges that
face any effort to meaningfully revise the Common Rule. The data from the IRB and the research
participant studies show that the IRB efforts to
achieve protection via the best possible consent
document are consistently moderated by both the
IRB processes and the decision–making process
that the research participants bring to the research
enterprise. Even the most carefully designed forms
may be of limited utility as research participants
seem to overlook information in the consent form
and instead largely base their decisions on a pervasive level of trust—trust of the one who suggests participation (trusted physician), trust in the
system (safe and not allowed if dangerous), trust
in the product (new gold standard), and trust in
the outcome (personal and humanitarian good).
The HHS comments from researchers, administrators, and individuals with commercial interests in
research suggest wide discrepancies among the
various stakeholders’ viewpoints on the effectiveness of current protocols and what may be important going forward. It is critical to hear more from
the one voice less well represented by the public
comments—that of the research participant. The
limited input offered from the perspective of the
research participant may represent an important
gap in knowledge, as findings from the research
participant study suggest that participants have
distinct views, perspectives, and concerns on what
constitutes full and informed consent.
Although the qualitative design of this research
limits the generalizability of findings, it has identified themes, concerns, concepts, and approaches
that are relevant to discussions about the protection of human research subjects. To truly identify
areas where protection and informed consent can
be enhanced, we need to think deeply about the
IRB’s mission including management of the explicit
goal of protecting human subjects and the implicit
goals of protecting the interests of researchers
and advancing meritorious science. We also need

to better understand the values, beliefs, and the
expectations that participants bring to their decisions about research participation and whether
other information, such as information about
researcher compensation or the reason for conducting the study, may be pivotal for the participant’s
decision making. We need to better understand
what researchers and administrators deem effective, reasonable and doable. In short, we need to
continually ask ourselves how we can best hear all
of the voices who are involved in the research enterprise—those who have a financial, institutional, or
professional stake and those who put their health
and well–being on the line on behalf of science. The
benefits of such inclusive conversations could be
considerable; greater awareness and understanding
among key stakeholders may reinforce trust and
confidence in the research enterprise and ultimately
lead to a more ethically attuned research environment, one in which the participant becomes not
just protected but informed, and not just a subject
but a partner.
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